• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
OCC
Click for more information
2.40% 61.0¢

ORTHOCELL LIMITED - Announcements

Market Cap $95.35M  ! watchlist Created with Sketch. Add to my watchlist

Orthocell Limited is an Australia-based regenerative medicine company. The Company is... Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is a sterile, resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen scaffold used in peripheral nerve repair. OrthoACI or autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
OCC Orthocells Ortho-ATI Shoulder Tendon Study on Track06/03/19
OCC Half Yearly Report and AccountsPRICE SENSITIVE27/02/19
OCC Ceasing to be a substantial holder QXZ15/02/19
OCC Orthocells Ortho-ATI shows 82% success ratePRICE SENSITIVE13/02/19
OCC Appendix 4C - QuarterlyPRICE SENSITIVE31/01/19
OCC Appendix 3B and Notice Under Section 708A31/12/18
OCC Appendix 3B and Notice Under Section 708A18/12/18
OCC Placement Completion18/12/18
OCC CelGro Approved in Key UK Public Dental HospitalPRICE SENSITIVE11/12/18
OCC Share Placement Successfully Raises $1.8mPRICE SENSITIVE11/12/18
OCC Trading HaltPRICE SENSITIVE07/12/18
OCC Patient Treatment Completed in Dental Implant StudyPRICE SENSITIVE28/11/18
OCC Results of Meeting19/11/18
OCC OCC Receives New Patents for Celgro Platform TechnologyPRICE SENSITIVE02/11/18
OCC Appendix 4C - QuarterlyPRICE SENSITIVE31/10/18
OCC Investor UpdatePRICE SENSITIVE31/10/18
OCC Orthocell Secures CelGro Patent Protection in JapanPRICE SENSITIVE23/10/18
OCC Notice of Annual General Meeting/Proxy Form19/10/18
OCC Successful CelGro Results Presented at Key Euro ConferencePRICE SENSITIVE18/10/18
OCC Appendix 4G17/10/18
OCC Annual Report to shareholders17/10/18
OCC Orthocell Receives A$2.5m R&D tax Incentive RefundPRICE SENSITIVE11/10/18
OCC CelGro Used as Artificial Periosteum Repairs BonePRICE SENSITIVE04/10/18
OCC Appendix 3B04/10/18
OCC CelGro used in Nano Medicine BreakthroughPRICE SENSITIVE27/09/18
OCC Preliminary Final Report and Annual Financial StatementsPRICE SENSITIVE31/08/18
OCC Appendix 4C - QuarterlyPRICE SENSITIVE31/07/18
OCC OCC Reports First Product Use and Sales of CelGro in IrelandPRICE SENSITIVE26/07/18
OCC CelGro Pre-Submission Meeting Completed with the FDAPRICE SENSITIVE24/07/18
OCC Orthocell Receives New Patent for Celgro Platform TechnologyPRICE SENSITIVE20/07/18
OCC OCC Reports First Product Use and Sales of Celgro in ItalyPRICE SENSITIVE17/07/18
OCC Orthocell Appoints Exclusive Distributor in the UKPRICE SENSITIVE10/07/18
OCC New CelGro Arthroscopic Tendon Regeneration Study CommencesPRICE SENSITIVE02/07/18
OCC Dr. Jonathan Bell Appointed to Orthocell Advisory Board25/06/18
OCC Orthocell Announces Successful Ortho-ATI Study ResultsPRICE SENSITIVE14/06/18
OCC Orthocell Announces Successful Tendon Study ResultsPRICE SENSITIVE06/06/18
OCC First Product Use and Sales of CelGro in PolandPRICE SENSITIVE31/05/18
OCC Orthocell Secures CelGro Patent Protection in EuropePRICE SENSITIVE24/05/18
OCC First Product Use and Sale of CelGro in EuropePRICE SENSITIVE22/05/18
OCC 10th Patient Treatment Milestone in Human Tendon StudyPRICE SENSITIVE17/05/18
OCC Change of Director's Interest Notice * 511/05/18
OCC Appendix 3B and Notice Under Section 708A10/05/18
OCC Orthocell Extends Distributor Network in the EUPRICE SENSITIVE08/05/18
OCC Results of Meeting07/05/18
OCC Orthocell Announces Successful Bone Repair Study ResultsPRICE SENSITIVE01/05/18
OCC Appendix 4C - quarterlyPRICE SENSITIVE30/04/18
OCC Orthocell Appoints First Distributor in the EUPRICE SENSITIVE30/04/18
OCC Updated Investor Presentation16/04/18
OCC Investor Update09/04/18
OCC Notice of General Meeting/Proxy Form06/04/18
OCC Cedrus Investments Initiation of Coverage04/04/18
OCC Prof. Giuseppe Luongo Appointed to Orthocell Advisory Board26/03/18
OCC NDF Research Initiation of Coverage20/03/18
OCC Prof. Massimo Simion Appointed to Orthocell Advisory Board19/03/18
OCC FDA Publication Supports Regenerative Medicine Acceleration15/03/18
OCC Half Yearly Report and AccountsPRICE SENSITIVE23/02/18
OCC New Cell Factory Patent Granted in the USPRICE SENSITIVE22/02/18
OCC Positive CelGro Study Results in ACL ReconstructionPRICE SENSITIVE05/02/18
OCC Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
OCC Orthocell Granted Canadian Tendon Regeneration PatentPRICE SENSITIVE31/01/18
OCC Change in substantial holding MHZ30/01/18
OCC Change in substantial holding PA19/01/18
OCC Change in substantial holding SRV19/01/18
OCC Change in substantial holding MC19/01/18
OCC Change in substantial holding QXZ19/01/18
OCC New Patent for Suture-Less Repair of Soft Tissue SecuredPRICE SENSITIVE18/01/18
OCC Successful Completion of Share Purchase Plan12/01/18
OCC Appendix 3B12/01/18
OCC Orthocell featured at Biotech Showcase in San Francisco09/01/18
OCC 50% Patient Treatment Milestone in Human Nerve TrialPRICE SENSITIVE02/01/18
OCC Share Purchase Plan Closing Date Extended28/12/17
OCC Appendix 3B and Notice Under Section 708A20/12/17
OCC Invitation to Participate in Share Purchase Plan15/12/17
OCC Notice Under ASIC Class Order CO 09/42515/12/17
OCC Orthocell Granted European Tendon Regeneration PatentPRICE SENSITIVE15/12/17
OCC Orthocell Featured in CommSec Executive Series Interview14/12/17
OCC Placement and Share Purchase PlanPRICE SENSITIVE13/12/17
OCC Trading HaltPRICE SENSITIVE11/12/17
OCC Ortho-ATI Case Study PublicationPRICE SENSITIVE08/12/17
OCC Orthocell Commences Treatment of its 1,000th Patient07/12/17
OCC Orthocell Granted European Cartilage Regeneration PatentPRICE SENSITIVE01/12/17
OCC Change of Director's Interest Notice - options expiry * 530/11/17
OCC FDA Comprehensive Regenerative Medicine Policy Framework27/11/17
OCC Company Update Presentation21/11/17
OCC Results of Meeting15/11/17
OCC Orthocell Receives CE Mark for CelGroPRICE SENSITIVE09/11/17
OCC Trading HaltPRICE SENSITIVE08/11/17
OCC Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
OCC Orthocell receives R&D tax incentive refundPRICE SENSITIVE24/10/17
OCC Company Update Presentation17/10/17
OCC Orthocell Granted CelGro Patent Protection in CanadaPRICE SENSITIVE16/10/17
OCC Notice of Annual General Meeting/Proxy FormPRICE SENSITIVE13/10/17
OCC Surgical Specialties Appointed as Exclusive DistributorPRICE SENSITIVE11/10/17
OCC Orthocell Receives New Patent for Celgro Platform TechnologyPRICE SENSITIVE21/09/17
OCC Appendix 4G14/09/17
OCC Annual Report to shareholders14/09/17
OCC Celgro Positive Safety and Performance in Human Hip StudyPRICE SENSITIVE06/09/17
OCC 1st Patient Recruited in Ortho-ATI Shoulder Tendon StudyPRICE SENSITIVE05/09/17
OCC Preliminary Final ReportPRICE SENSITIVE31/08/17
OCC Change of Director's Interest Notice SW08/08/17
OCC Orthocells Ortho-ATI Shoulder Tendon Study on Track
06/03/19
OCC Half Yearly Report and Accounts
27/02/19PRICE SENSITIVE
OCC Ceasing to be a substantial holder QXZ
15/02/19
OCC Orthocells Ortho-ATI shows 82% success rate
13/02/19PRICE SENSITIVE
OCC Appendix 4C - Quarterly
31/01/19PRICE SENSITIVE
OCC Appendix 3B and Notice Under Section 708A
31/12/18
OCC Appendix 3B and Notice Under Section 708A
18/12/18
OCC Placement Completion
18/12/18
OCC CelGro Approved in Key UK Public Dental Hospital
11/12/18PRICE SENSITIVE
OCC Share Placement Successfully Raises $1.8m
11/12/18PRICE SENSITIVE
OCC Trading Halt
07/12/18PRICE SENSITIVE
OCC Patient Treatment Completed in Dental Implant Study
28/11/18PRICE SENSITIVE
OCC Results of Meeting
19/11/18
OCC OCC Receives New Patents for Celgro Platform Technology
02/11/18PRICE SENSITIVE
OCC Appendix 4C - Quarterly
31/10/18PRICE SENSITIVE
OCC Investor Update
31/10/18PRICE SENSITIVE
OCC Orthocell Secures CelGro Patent Protection in Japan
23/10/18PRICE SENSITIVE
OCC Notice of Annual General Meeting/Proxy Form
19/10/18
OCC Successful CelGro Results Presented at Key Euro Conference
18/10/18PRICE SENSITIVE
OCC Appendix 4G
17/10/18
OCC Annual Report to shareholders
17/10/18
OCC Orthocell Receives A$2.5m R&D tax Incentive Refund
11/10/18PRICE SENSITIVE
OCC CelGro Used as Artificial Periosteum Repairs Bone
04/10/18PRICE SENSITIVE
OCC Appendix 3B
04/10/18
OCC CelGro used in Nano Medicine Breakthrough
27/09/18PRICE SENSITIVE
OCC Preliminary Final Report and Annual Financial Statements
31/08/18PRICE SENSITIVE
OCC Appendix 4C - Quarterly
31/07/18PRICE SENSITIVE
OCC OCC Reports First Product Use and Sales of CelGro in Ireland
26/07/18PRICE SENSITIVE
OCC CelGro Pre-Submission Meeting Completed with the FDA
24/07/18PRICE SENSITIVE
OCC Orthocell Receives New Patent for Celgro Platform Technology
20/07/18PRICE SENSITIVE
OCC OCC Reports First Product Use and Sales of Celgro in Italy
17/07/18PRICE SENSITIVE
OCC Orthocell Appoints Exclusive Distributor in the UK
10/07/18PRICE SENSITIVE
OCC New CelGro Arthroscopic Tendon Regeneration Study Commences
02/07/18PRICE SENSITIVE
OCC Dr. Jonathan Bell Appointed to Orthocell Advisory Board
25/06/18
OCC Orthocell Announces Successful Ortho-ATI Study Results
14/06/18PRICE SENSITIVE
OCC Orthocell Announces Successful Tendon Study Results
06/06/18PRICE SENSITIVE
OCC First Product Use and Sales of CelGro in Poland
31/05/18PRICE SENSITIVE
OCC Orthocell Secures CelGro Patent Protection in Europe
24/05/18PRICE SENSITIVE
OCC First Product Use and Sale of CelGro in Europe
22/05/18PRICE SENSITIVE
OCC 10th Patient Treatment Milestone in Human Tendon Study
17/05/18PRICE SENSITIVE
OCC Change of Director's Interest Notice * 5
11/05/18
OCC Appendix 3B and Notice Under Section 708A
10/05/18
OCC Orthocell Extends Distributor Network in the EU
08/05/18PRICE SENSITIVE
OCC Results of Meeting
07/05/18
OCC Orthocell Announces Successful Bone Repair Study Results
01/05/18PRICE SENSITIVE
OCC Appendix 4C - quarterly
30/04/18PRICE SENSITIVE
OCC Orthocell Appoints First Distributor in the EU
30/04/18PRICE SENSITIVE
OCC Updated Investor Presentation
16/04/18
OCC Investor Update
09/04/18
OCC Notice of General Meeting/Proxy Form
06/04/18
OCC Cedrus Investments Initiation of Coverage
04/04/18
OCC Prof. Giuseppe Luongo Appointed to Orthocell Advisory Board
26/03/18
OCC NDF Research Initiation of Coverage
20/03/18
OCC Prof. Massimo Simion Appointed to Orthocell Advisory Board
19/03/18
OCC FDA Publication Supports Regenerative Medicine Acceleration
15/03/18
OCC Half Yearly Report and Accounts
23/02/18PRICE SENSITIVE
OCC New Cell Factory Patent Granted in the US
22/02/18PRICE SENSITIVE
OCC Positive CelGro Study Results in ACL Reconstruction
05/02/18PRICE SENSITIVE
OCC Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
OCC Orthocell Granted Canadian Tendon Regeneration Patent
31/01/18PRICE SENSITIVE
OCC Change in substantial holding MHZ
30/01/18
OCC Change in substantial holding PA
19/01/18
OCC Change in substantial holding SRV
19/01/18
OCC Change in substantial holding MC
19/01/18
OCC Change in substantial holding QXZ
19/01/18
OCC New Patent for Suture-Less Repair of Soft Tissue Secured
18/01/18PRICE SENSITIVE
OCC Successful Completion of Share Purchase Plan
12/01/18
OCC Appendix 3B
12/01/18
OCC Orthocell featured at Biotech Showcase in San Francisco
09/01/18
OCC 50% Patient Treatment Milestone in Human Nerve Trial
02/01/18PRICE SENSITIVE
OCC Share Purchase Plan Closing Date Extended
28/12/17
OCC Appendix 3B and Notice Under Section 708A
20/12/17
OCC Invitation to Participate in Share Purchase Plan
15/12/17
OCC Notice Under ASIC Class Order CO 09/425
15/12/17
OCC Orthocell Granted European Tendon Regeneration Patent
15/12/17PRICE SENSITIVE
OCC Orthocell Featured in CommSec Executive Series Interview
14/12/17
OCC Placement and Share Purchase Plan
13/12/17PRICE SENSITIVE
OCC Trading Halt
11/12/17PRICE SENSITIVE
OCC Ortho-ATI Case Study Publication
08/12/17PRICE SENSITIVE
OCC Orthocell Commences Treatment of its 1,000th Patient
07/12/17
OCC Orthocell Granted European Cartilage Regeneration Patent
01/12/17PRICE SENSITIVE
OCC Change of Director's Interest Notice - options expiry * 5
30/11/17
OCC FDA Comprehensive Regenerative Medicine Policy Framework
27/11/17
OCC Company Update Presentation
21/11/17
OCC Results of Meeting
15/11/17
OCC Orthocell Receives CE Mark for CelGro
09/11/17PRICE SENSITIVE
OCC Trading Halt
08/11/17PRICE SENSITIVE
OCC Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
OCC Orthocell receives R&D tax incentive refund
24/10/17PRICE SENSITIVE
OCC Company Update Presentation
17/10/17
OCC Orthocell Granted CelGro Patent Protection in Canada
16/10/17PRICE SENSITIVE
OCC Notice of Annual General Meeting/Proxy Form
13/10/17PRICE SENSITIVE
OCC Surgical Specialties Appointed as Exclusive Distributor
11/10/17PRICE SENSITIVE
OCC Orthocell Receives New Patent for Celgro Platform Technology
21/09/17PRICE SENSITIVE
OCC Appendix 4G
14/09/17
OCC Annual Report to shareholders
14/09/17
OCC Celgro Positive Safety and Performance in Human Hip Study
06/09/17PRICE SENSITIVE
OCC 1st Patient Recruited in Ortho-ATI Shoulder Tendon Study
05/09/17PRICE SENSITIVE
OCC Preliminary Final Report
31/08/17PRICE SENSITIVE
OCC Change of Director's Interest Notice SW
08/08/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
61.0¢ 		Change
-0.015(2.40%) 		Mkt cap ! $95.35M
Open High Low Value Volume
63.0¢ 63.0¢ 61.0¢ $310.1K 501.9K

Buyers (Bids)

No. Vol. Price($)
9 55956 61.0¢
 

Sellers (Offers)

Price($) Vol. No.
62.5¢ 62141 3
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
61.5¢ 		  Change
-0.015 ( 0.68 %)
Open High Low Volume
62.0¢ 62.5¢ 61.5¢ 145088
Last updated 15.55pm 21/11/2024 ?
OCC (ASX) Chart

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.